Document is current
Any future updates will be listed below
-
Authors
Bertucci, François http://orcid.org/0000-0002-0157-0959
Gonçalves, Anthony
Guille, Arnaud
Adelaïde, José
Garnier, Séverine
Carbuccia, Nadine
Billon, Emilien
Finetti, Pascal
Sfumato, Patrick
Monneur, Audrey
Pécheux, Christophe
Khran, Martin
Brunelle, Serge
Mescam, Lenaïg
Thomassin-Piana, Jeanne
Poizat, Flora
Charafe-Jauffret, Emmanuelle
Turrini, Olivier
Lambaudie, Eric
Provansal, Magali
Extra, Jean-Marc
Madroszyk, Anne
Gilabert, Marine
Sabatier, Renaud
Vicier, Cécile
Mamessier, Emilie
Chabannon, Christian
Pakradouni, Jihane
Viens, Patrice
André, Fabrice
Gravis, Gwenaelle
Popovici, Cornel
Birnbaum, Daniel
Chaffanet, Max
-
Funding
Funding for this research was provided by:
SIRIC
Ligue Contre le Cancer (EL2016, EL2019)
Ruban Rose
Association La Marie-Do
Fondation Groupe EDF
Centre d’Investigations Cliniques (CICp1409)
- License Information
-
More Information
Article History
Received: 27 August 2020
Accepted: 27 April 2021
First Online: 18 May 2021
Declarations
:
: The PERMED-01 trial was approved by the French National Agency for Medicines and Health Products Safety ANSM; ref 140823B-12, a national ethics committee (CPP Sud-Méditerranée I; ref 1456), and our Institut Paoli-Calmettes Institutional Review Board (reference number: 2014-003). All patients gave their informed consent for inclusion, biopsy, and genomic analysis and to participate in the study. The research was conducted in strict compliance with the Helsinki Declaration.
: Not applicable.
: The authors declare that they have no competing interests.
